Wedbush Expects Higher Earnings for Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Equities researchers at Wedbush raised their Q1 2025 earnings per share estimates for Fennec Pharmaceuticals in a report issued on Monday, March 10th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.10) per share for the quarter, up from their prior estimate of ($0.14). Wedbush currently has a “Outperform” rating and a $13.00 target price on the stock. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is ($0.11) per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at $0.33 EPS, Q4 2025 earnings at $0.42 EPS and FY2026 earnings at $2.20 EPS.

Several other equities research analysts have also commented on FENC. Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a research report on Tuesday.

Fennec Pharmaceuticals Stock Up 1.6 %

Shares of NASDAQ:FENC opened at $6.50 on Thursday. Fennec Pharmaceuticals has a 52-week low of $3.96 and a 52-week high of $11.49. The stock’s fifty day simple moving average is $6.39 and its 200-day simple moving average is $5.63. The company has a market capitalization of $179.15 million, a P/E ratio of -64.99 and a beta of 0.36.

Institutional Investors Weigh In On Fennec Pharmaceuticals

Several hedge funds have recently bought and sold shares of FENC. Intech Investment Management LLC bought a new stake in shares of Fennec Pharmaceuticals during the fourth quarter worth $69,000. Wells Fargo & Company MN grew its position in Fennec Pharmaceuticals by 31.6% in the 4th quarter. Wells Fargo & Company MN now owns 13,152 shares of the company’s stock worth $83,000 after purchasing an additional 3,155 shares in the last quarter. Franklin Resources Inc. lifted its stake in Fennec Pharmaceuticals by 18.7% in the 3rd quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock worth $74,000 after purchasing an additional 2,330 shares in the last quarter. Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of Fennec Pharmaceuticals during the 4th quarter valued at $97,000. Finally, MetLife Investment Management LLC bought a new position in shares of Fennec Pharmaceuticals during the 4th quarter valued at $99,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Fennec Pharmaceuticals

In related news, Director Rosty Raykov sold 10,000 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $6.79, for a total transaction of $67,900.00. Following the sale, the director now owns 68,725 shares of the company’s stock, valued at approximately $466,642.75. This trade represents a 12.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 31,186 shares of company stock valued at $203,389 in the last quarter. Corporate insiders own 10.98% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.